{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:46:05Z","timestamp":1779176765839,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Spanish Academy of Dermatology and Venereology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mucocutaneous Beh\u00e7et disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Beh\u00e7et disease-associated aphthosis in routine clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a single-cohort ambispective observational study. Eleven patients with Beh\u00e7et disease treated with roflumilast participated. Data collection included demographic, clinical and outcome variables. Statistical analysis compared 12 weeks of treatment with roflumilast with a previous period without treatment and with a period when the previous treatment was used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During treatment with roflumilast, a reduction in flare-ups and oral ulcers was observed compared with the untreated period and the previous treatment period. A reduction in genital ulcers, pain and ulcer duration was observed between the without treatment period and the roflumilast treatment period. Adverse effects occurred in 54% of patients, most of which were self-limiting or manageable with dose adjustment. No patients withdrew treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Roflumilast appears to be a potential option in the treatment of Beh\u00e7et disease with favourable effectiveness, safety and tolerability profiles. Although further research is needed, roflumilast offers a promising treatment option for Beh\u00e7et disease-associated aphthosis, which could improve the patients\u2019 quality of life and address unmet therapeutic needs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae284","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T03:10:52Z","timestamp":1721877052000},"page":"62-68","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Beh\u00e7et disease with oral roflumilast: an\u00a0observational study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-780X","authenticated-orcid":false,"given":"Rodrigo","family":"Pe\u00f1uelas Leal","sequence":"first","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-7428","authenticated-orcid":false,"given":"Carolina","family":"Labrandero Hoyos","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Amancio","family":"Pe\u00f1uelas Ruiz","sequence":"additional","affiliation":[{"name":"Gandia Public Health Centre , Gand\u00eda ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-1999","authenticated-orcid":false,"given":"Leticia","family":"Bag\u00e1n","sequence":"additional","affiliation":[{"name":"Cli\u0301nica Odontolo\u0301gica de Medicina Buccal , Valencia ,","place":["Spain"]},{"name":"Oral Medicine Department, University of Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Zaragoza Ninet","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"S\u00e1nchez Carazo","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"P\u00e9rez Pastor","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-3107","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Grau Echevarr\u00eda","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altea","family":"Esteve Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-3481","authenticated-orcid":false,"given":"Malena","family":"Finello","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7667-600X","authenticated-orcid":false,"given":"Daniel","family":"Blaya Imbernon","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Dios Guill\u00e1n","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Aguilar Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Puerta del Mar , Ca\u0301diz ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-2916","authenticated-orcid":false,"given":"Jose\u0301","family":"Baga\u0301n","sequence":"additional","affiliation":[{"name":"Oral Medicine Department, University of Valencia , Valencia ,","place":["Spain"]},{"name":"Department of Oral and Maxillofacial Surgery, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Alegre De Miquel","sequence":"additional","affiliation":[{"name":"Dermatology Department, Consorci Hospital General Universitari de Valencia , Valencia ,","place":["Spain"]},{"name":"Dermatology Department, University of Valencia , Valencia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2024122223554558300_llae284-B1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMra2305712","article-title":"Beh\u00e7et\u2019s syndrome","volume":"390","author":"Saadoun","year":"2024","journal-title":"N Engl J Med"},{"key":"2024122223554558300_llae284-B2","first-page":"1461","article-title":"Beh\u00e7et\u2019s syndrome: one year in review 2022","volume":"40","author":"Hatemi","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2024122223554558300_llae284-B3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024122223554558300_llae284-B4","first-page":"1078","article-title":"Criteria for diagnosis of Behc\u0327et\u2019s disease","volume":"335","author":"International Study Group for Behc\u0327et\u2019s Disease","year":"1990","journal-title":"Lancet"},{"key":"2024122223554558300_llae284-B5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024122223554558300_llae284-B6","first-page":"808","article-title":"update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024122223554558300_llae284-B7","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"2024122223554558300_llae284-B8","article-title":"Otezla (apremilast)","author":"European Medicines Agency"},{"key":"2024122223554558300_llae284-B9","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"2024122223554558300_llae284-B10","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"2024122223554558300_llae284-B11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ced\/llad189","article-title":"Refractory Beh\u00e7et\u2019s disease successfully treated with roflumilast","volume":"48","author":"Pe\u00f1uelas Leal","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2024122223554558300_llae284-B12","article-title":"Daxas (roflumilast). European Medicines Agency","author":"European Medicines Agency"},{"key":"2024122223554558300_llae284-B13","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1111\/jdv.18647","article-title":"Long-term clearance of severe plaque psoriasis with oral roflumilast","volume":"37","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024122223554558300_llae284-B14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/ced\/llae229","article-title":"Treatment of palmoplantar psoriasis with oral roflumilast: a case series","volume":"49","author":"Lasheras-P\u00e9rez","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2024122223554558300_llae284-B15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ced\/llad041","article-title":"Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast","volume":"48","author":"Fage","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2024122223554558300_llae284-B16","first-page":"e467","article-title":"Severe multi-refractory Sneddon-Wilkinson disease, with fast response to oral roflumilast treatment","volume":"38","author":"Pe\u00f1uelas Leal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024122223554558300_llae284-B17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"key":"2024122223554558300_llae284-B18","article-title":"Apremilast (Otezla) European Medicines Agency","author":"European Medicines Agency"},{"key":"2024122223554558300_llae284-B19","article-title":"Apremilast (Otezla). Highlights of prescribing information","author":"US Food and Drug Administration"},{"key":"2024122223554558300_llae284-B20","article-title":"Otezla 30\u2005mg comprimidos RECUBIERTOS con pelicula","author":"Vademecum"},{"key":"2024122223554558300_llae284-B21","article-title":"Support and savings: Otezla\u00ae (APREMILAST) for plaque psoriasis","author":"Amgen, Inc"},{"key":"2024122223554558300_llae284-B22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Beh\u00e7et\u2019s disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"2024122223554558300_llae284-B23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14740338.2016.1199683","article-title":"Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis","volume":"15","author":"Rogliani","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2024122223554558300_llae284-B24","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1378\/chest.15-0664","article-title":"Roflumilast in COPD","volume":"148","author":"Worndl","year":"2015","journal-title":"Chest"},{"key":"2024122223554558300_llae284-B25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pupt.2014.10.002","article-title":"Roflumilast added to triple therapy in patients with severe COPD: a real life study","volume":"30","author":"Mu\u00f1oz-Esquerre","year":"2015","journal-title":"Pulmo Pharmacol Ther"},{"key":"2024122223554558300_llae284-B26","article-title":"Daxas 250 microgramos comprimidos","author":"Vademecum"},{"key":"2024122223554558300_llae284-B27","article-title":"Roflumilast aurovitas 500 microgramos comprimidos EFG","author":"Vademecum"},{"key":"2024122223554558300_llae284-B28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amsu.2020.03.010","article-title":"Impact of disease activity on health related quality of life in patients with Beh\u00e7et\u2019s disease: a cross-sectional study","volume":"54","author":"Gorial","year":"2020","journal-title":"Ann Med Surg"},{"key":"2024122223554558300_llae284-B29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1601-0825.2005.01173.x","article-title":"Oral health related quality of life is affected by disease activity in Beh\u00e7et\u2019s disease","volume":"12","author":"Mumcu","year":"2006","journal-title":"Oral Dis"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae284\/60750874\/llae284.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/62\/60750874\/llae284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/62\/60750874\/llae284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:55:59Z","timestamp":1734911759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/62\/7719364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae284","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,24]]}}}